Gain Therapeutics Competitors

Gain Therapeutics (NASDAQ:GANX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Gain Therapeutics and Sigilon Therapeutics, as reported by MarketBeat.com.

Gain Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 220.17%. Sigilon Therapeutics has a consensus target price of $53.75, indicating a potential upside of 305.66%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Gain Therapeutics.

Earnings and Valuation

This table compares Gain Therapeutics and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Gain Therapeutics and Sigilon Therapeutics' net margins, return on equity and return on assets.

Summary

Sigilon Therapeutics beats Gain Therapeutics on 2 of the 3 factors compared between the two stocks.

Angion Biomedica (NASDAQ:ANGN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Profitability

This table compares Angion Biomedica and Gain Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings for Angion Biomedica and Gain Therapeutics, as provided by MarketBeat.com.

Angion Biomedica currently has a consensus price target of $59.3333, indicating a potential upside of 316.67%. Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Angion Biomedica's higher possible upside, equities analysts clearly believe Angion Biomedica is more favorable than Gain Therapeutics.

Earnings & Valuation

This table compares Angion Biomedica and Gain Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Summary

Angion Biomedica beats Gain Therapeutics on 2 of the 2 factors compared between the two stocks.

Landos Biopharma (NASDAQ:LABP) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Landos Biopharma and Gain Therapeutics, as reported by MarketBeat.com.

Landos Biopharma presently has a consensus price target of $25.50, indicating a potential upside of 147.57%. Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Landos Biopharma.

Valuation & Earnings

This table compares Landos Biopharma and Gain Therapeutics' gross revenue, earnings per share and valuation.

Profitability

This table compares Landos Biopharma and Gain Therapeutics' net margins, return on equity and return on assets.

Summary

Gain Therapeutics beats Landos Biopharma on 2 of the 3 factors compared between the two stocks.

Rain Therapeutics (NASDAQ:RAIN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and target prices for Rain Therapeutics and Gain Therapeutics, as reported by MarketBeat.com.

Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Rain Therapeutics.

Valuation & Earnings

This table compares Rain Therapeutics and Gain Therapeutics' gross revenue, earnings per share and valuation.

Profitability

This table compares Rain Therapeutics and Gain Therapeutics' net margins, return on equity and return on assets.

Summary

Gain Therapeutics beats Rain Therapeutics on 2 of the 2 factors compared between the two stocks.

NexImmune (NASDAQ:NEXI) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Profitability

This table compares NexImmune and Gain Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for NexImmune and Gain Therapeutics, as reported by MarketBeat.com.

NexImmune currently has a consensus price target of $33.3333, suggesting a potential upside of 94.36%. Gain Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 220.17%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than NexImmune.

Valuation & Earnings

This table compares NexImmune and Gain Therapeutics' revenue, earnings per share and valuation.

Terns Pharmaceuticals (NASDAQ:TERN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Profitability

This table compares Terns Pharmaceuticals and Gain Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Terns Pharmaceuticals and Gain Therapeutics' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Terns Pharmaceuticals and Gain Therapeutics, as reported by MarketBeat.com.

Terns Pharmaceuticals currently has a consensus price target of $30.50, indicating a potential upside of 90.74%. Gain Therapeutics has a consensus price target of $30.00, indicating a potential upside of 220.17%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Terns Pharmaceuticals.